# Safety, Tolerability, and Pharmacokinetics (PK) of CTP-499

> **NCT01328821** · PHASE1 · COMPLETED · sponsor: **Concert Pharmaceuticals** · enrollment: 38 (actual)

## Conditions studied

- Diabetic Nephropathy

## Interventions

- **DRUG:** CTP-499
- **DRUG:** CTP-499

## Key facts

- **NCT ID:** NCT01328821
- **Lead sponsor:** Concert Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-03
- **Primary completion:** 2011-04
- **Final completion:** 2011-06
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2011-10-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01328821

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01328821, "Safety, Tolerability, and Pharmacokinetics (PK) of CTP-499". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT01328821. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*